Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 4/20 | 0.87 |
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.59 |
| ▸ | FDPS known ✓ | P14324 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022053 | 0.98 | CA1 (0.86) | CA1CA2NFKB1CYP3A4TSHR | |
| SCHEMBL2734017 | 0.95 | CA1 (0.83) | CA1CA2NFKB1CYP3A4TSHR | |
| SCHEMBL6866750 | 0.95 | CA1 (0.83) | CA1CA2NFKB1CYP3A4TSHR | |
| SCHEMBL2732403 | 0.95 | CA1 (0.83) | CA1CA2NFKB1CYP3A4TSHR | |
| SCHEMBL2734015 | 0.95 | CA1 (0.83) | CA1CA2NFKB1CYP3A4TSHR | |
| SCHEMBL9862909 | 0.95 | CA1 (0.83) | CA1CA2NFKB1CYP3A4TSHR | |
| SCHEMBL2732972 | 0.95 | CA1 (0.83) | CA1CA2NFKB1CYP3A4TSHR | |
| SCHEMBL15129235 | 0.95 | CA1 (0.83) | CA1CA2NFKB1CYP3A4TSHR | |
| SCHEMBL8031682 | 0.95 | CA1 (0.83) | CA1CA2NFKB1CYP3A4TSHR | |
| SCHEMBL15820922 | 0.95 | CA1 (0.83) | CA1CA2NFKB1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282806-A1 | CHEMICAL SYNTHESIS METHOD FOR DISACCHARIDE FRAGMENT OF VIBRIO VULNIFICUS BIOTYPE 2 SEROVAR A O-ANTIGEN | JIANGNAN UNIVERSITY (CN) | 2025-09-11 | — | — | US | disclosed |
| CN-118496286-A | Chemical synthesis method of vibrio vulnificus organism type 2A serotype O-antigen disaccharide fragment | 江南大学 | 2024-08-16 | — | — | CN | disclosed |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11541029-B2 | High penetration compositions and their applications | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| EP-2621457-B1 | OXIDATIVE STABLE MICELLAR COMPOSITIONS | SWISSDENT COSMETICS AG (CH) | 2017-08-23 | — | — | EP | disclosed |
| US-9676777-B2 | Compounds useful for producing an optically active diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| EP-2657234-B1 | OPTICALLY-ACTIVE DIAZABICYCLOOCTANE DERIVATIVE AND METHOD FOR MANUFACTURING SAME | MEIJI SEIKA PHARMA CO LTD (JP) | 2017-01-11 | — | — | EP | disclosed |
| US-20160137645-A1 | COMPOUNDS USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| EP-2776431-B1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-04 | — | — | EP | disclosed |
| US-9284273-B2 | Compounds useful for producing an optically active diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-03-15 | — | — | US | disclosed |
| US-20040266905-A1 | Hardenable mixture of substrances, production method and use thereof | BASF COATINGS AKTIENGESELLSCHAFT (DE) | 2004-12-30 | — | — | US | disclosed |
| EP-1440103-A1 | HARDENABLE MIXTURE OF SUBSTANCES, PRODUCTION METHOD AND USE THEREOF | BASF Coatings AG (DE) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003091350-A1 | THERMALLY CURABLE, THIXOTROPIC MIXTURES CONTAINING CARBAMATE AND/OR ALLOPHANATE GROUPS | BASF COATINGS AG (DE) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003037952-A1 | HARDENABLE MIXTURE OF SUBSTANCES, PRODUCTION METHOD AND USE THEREOF | BASF COATINGS AG (DE) | 2003-05-08 | — | — | WO | disclosed |
| EP-0597401-A2 | Production of penem | Takeda Chemical Industries, Ltd. (JP) | 1994-05-18 | — | — | EP | disclosed |
| WO-1985004404-A1 | CEPHALOSPORINS | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1985-10-10 | — | — | WO | disclosed |
| EP-0156771-A2 | Cephalosporins | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1985-10-02 | — | — | EP | disclosed |
| US-4378314-A | FOR PENICILLINS AND CEPHALOSPORINS | BRISTOL MYERS COMPANY (US) | 1983-03-29 | — | — | US | disclosed |
| US-4272437-A | PENICILLINS | BRISTOL-MYERS COMPANY (US) | 1981-06-09 | — | — | US | disclosed |
| US-4068074-A | BACTERICIDES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137645-A1 | COMPOUNDS USEFUL FOR PRODUCING AN OPTICALLY ACTIVE DIAZABICYCLOOCTANE COMPOUND | CBR1, CBR3, DOHH | CA1 850/4885CA2 18/4885FDPS 682/4885 |
| US-20250282806-A1 | CHEMICAL SYNTHESIS METHOD FOR DISACCHARIDE FRAGMENT OF VIBRIO VULNIFICUS BIOTYPE 2 SEROVAR A O-ANTIGEN | OGA, DDOST, FUT6 | CA1 530/4885CA2 197/4885FDPS 1146/4885 |
| US-11541029-B2 | High penetration compositions and their applications | SLC19A1, HIRA, SLC43A1 | CA1 3305/4885CA2 4516/4885FDPS 1709/4885 |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC5A7, SLC19A1, SLC43A1 | CA1 2655/4885CA2 3495/4885FDPS 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.